HPV vaccines not yet shown to be effective
It is not yet known how effective Gardasil and Cervarix are in preventing cervical cancer caused by the human papilloma virus (HPV), as studies conducted so far have been too brief concludes the latest .
It is also not yet known what duration of protection the vaccines offer, whether boosters will be required and whether the vaccine protects against infection with non-vaccine HPV types, the bulletin also states.
In the UK the bivalent Cervarix vaccine that offers protection against HPV types 16 and 18 has been chosen for the national screening programme. Cervarix does not offer any protection against genital warts, and the quadrivalent vaccine Gardasil, which offers protection against HPV types 6,11,16 and 18, should be offered to those requiring prevention against the HPV virus outside of the NHS vaccination scheme, the bulletin recommends.
However, both vaccines show high efficacy in preventing high-grade premalignant cervical lesions.
The bulletin also states that the NHS cervical screening programme will still be needed even for vaccinated women because 30 per cent of all cervical cancers are caused by HPV types not contained in the vaccines.
Citation: Electronicjuice URI: 10043678
Recommended from Pharmaceutical Press
A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.£54.00
An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.£38.00